NEW ORLEANS – A preclinical antibiotic candidate under development at Novabiotics Ltd. called Luminaderm, or NP-108, could potentially offer clinicians a new way to head off troublesome nasal Staphylococcus aureus infections, if early data showcased at the American Society for Microbiology's (ASM) Microbe 2017 meeting, holds up to scrutiny in the clinical trials.